If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Rete pegs (also known as rete processes, rete ridges or epidermal ridges) are the epithelial extensions that project into the underlying connective tissue in both skin and mucous membranes. In the epithelium of the mouth, the attached gingiva exhibit rete pegs, while the sulcular and junctional epithelia do not. Scar tissue lacks rete pegs and scars tend to shear off more easily than normal tissue as a result. Also known as papillae, they are downward thickenings of the epidermis between the dermal papillae.
There are no clear pharmacological guidelines for borderline personality disorder; psychotherapy is considered the primary treatment, with medications used cautiously for common comorbidities. Topiramate (strong), lamotrigine (moderate), and aripiprazole (moderate) show evidence for reducing anger and hostility in BPD. Evidence for ketamine in unresponsive depression in BPD is limited. Despite the lack of solid evidence, SSRIs and SNRIs are prescribed off-label for BPD and are typically considered adjunctive to psychotherapy. Pharmacological treatments appear to have minimal impact on brain activity and connectivity in borderline personality disorder patients during emotional processing, suggesting that observed neural alterations are largely independent of medication effects.
== Reduced-footprint cement == Growing environmental concerns and the increasing cost of fossil fuels have resulted, in many countries, in a sharp reduction of the resources needed to produce cement, as well as effluents (dust and exhaust gases). Reduced-footprint cement is a cementitious material that meets or exceeds the functional performance capabilities of Portland cement. Various techniques are under development. One is geopolymer cement, which incorporates recycled materials, thereby reducing consumption of raw materials, water, and energy. Another approach is to reduce or eliminate the production and release of damaging pollutants and greenhouse gasses, particularly CO2. Recycling old cement in electric arc furnaces is another approach. A team at the University of Edinburgh has developed the 'DUPE' process based on the microbial activity of Sporosarcina pasteurii, a bacterium precipitating calcium carbonate, which, when mixed with sand and urine, can produce mortar blocks with a compressive strength 70% of that of concrete.
== Honors and awards == Bumpus has received numerous recognitions from the United States government for her work. In 2016, President Obama awarded her a Presidential Early Career Award for Scientists and Engineers, "the highest honor bestowed by the United States Government on science and engineering professionals in the early stages of their independent research careers". She delivered the National Institute of General Medical Sciences (NIGMS) Director's Early-Career Investigator Lecture in 2017, and was the Congressional Biomedical Research Caucus's invited speaker in March 2018, lecturing about informing consumers about drug metabolism. Bumpus became a fellow of the American Association for the Advancement of Science, in its Section on Pharmaceutical Sciences, in 2021. In 2022, she was elected to the National Academy of Medicine. Additional awards she has received include:
Among the Buddhists there was a Tocharian (Tho-gar) king called Men-dre, or Polosi, or Ānandavarmā. He had the caves painted by restorers and painters: Mitradatta; Naravāhanadatta from the lands of the "naked ones" (Niganthas); Priyaratna from Romakam (Byzantine Empire); and other experts in restoration. The king of the Rgya-ser and King Men-dre's bodies were taken by Amitābha and he went to the land of bliss. When the son of the great king of Rgya-ser came to the fort of Mir-li, thanks to the power of prayer, all the "naked ones" (Niganthas) were killed by the followers of Kālacakra, and all of the Buddhist caves were restored. According to Sam van Schaik, "Mendre" could be the Indo-Greek king Menander, or the mythical king Manadhatṛ of Buddhist sources; "Polosi" could be a Chinese abbreviation for king Prasenajit; "Romakam" may be the Byzantine Empire; the "naked ones" would be the Niganthas. In Tibetan, the country named "Tho-gar" "Thod-kar" corresponds to Tokharistan (ancient Bactria).
Sources: en.wikipedia.org
Pickston founded Skinny Revolution to help people to lose weight after she gained 7 stone in 14 months, partly whilst pregnant, using a Wegovy (semaglutide) injection, which is a 2.4 mg injectable prescription medicine used as an appetite suppressant. Pickston is engaged to former West Ham United co-chairman David Sullivan. She has a son, Jake, with her former husband Mark Pickston. She lives in Hale Barns, in the house which was filmed for the Real Housewives of Cheshire episodes that she appeared in.
In September 2020, the US Food and Drug Administration (FDA) required the boxed warning for all benzodiazepine medicines to be updated to describe the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions consistently across all the medicines in the class.
=== US FDA approved === The US Food and Drug Administration (FDA) approves anti-obesity medications as an adjunctive therapy to diet and exercise for people for whom lifestyle changes do not result in sufficient weight loss. In the United States, semaglutide (Wegovy) is approved by the FDA for chronic weight management. The FDA guidelines say that a therapy may be approved if it results in weight loss that is statistically significant greater than placebo and generally at least five percent of body weight over six months that comes predominantly from fat mass. Some other prescription weight loss medications are stimulants, which are recommended only for short-term use, and thus are of limited usefulness for patients who may need to reduce weight over months or years. As of 2022, there is no pathway for approval for drugs that reduce fat mass without 5 percent overall weight loss, even if they significantly improve metabolic health; neither is there one for drugs that help patients maintain weight loss although this can be more challenging than losing weight. As of 2022, no medication has been discovered that would equal the effectiveness of bariatric surgery for long-term weight loss and improved health outcomes.
Carboxylates are the most common surfactants and comprise the carboxylate salts (soaps), such as sodium stearate. More specialized species include sodium lauroyl sarcosinate and carboxylate-based fluorosurfactants such as perfluorononanoate, perfluorooctanoate (PFOA or PFO).
The British critical psychiatrist Joanna Moncrieff has critiqued the use and study of ketamine and related drugs like psychedelics for treatment of psychiatric disorders, highlighting concerns including excessive hype around these drugs, questionable biologically-based theories of benefit, blurred lines between medical and recreational use, flawed clinical trial findings, financial conflicts of interest, strong expectancy effects and large placebo responses, small and short-term benefits over placebo, and their potential for difficult experiences and adverse effects, among others.
Sources: en.wikipedia.org
Beginning with the colonial era and intensifying after the South American states had gained their independence, large landowners appropriated all or most of the land and forced the Native population into bondage (known in Ecuador as Huasipungo, from Kichwa wasipunku, "front door"). Harsh conditions of exploitation repeatedly led to revolts by the Indigenous farmers, which were forcibly suppressed. The largest of these revolts occurred in 1780–1781 under the leadership of Husiy Qawriyil Kunturkanki (Túpac Amaru II).Some Indigenous farmers re-occupied their ancestors' lands and expelled the landlords during the takeover of governments by dictatorships in the middle of the 20th century, such as in 1952 in Bolivia (Víctor Paz Estenssoro) and 1968 in Peru (Juan Velasco Alvarado). The agrarian reforms included the expropriation of large landowners. In Bolivia, there was a redistribution of the land to the Indigenous population as their private property. This disrupted traditional Quechua and Aymara culture based on communal ownership, but ayllus has been retained up to the present time in remote regions, such as in the Peruvian Quechua community of Q'ero. The struggle for land rights continues up to the present time to be a political focal point of everyday Quechua life. The Kichwa ethnic groups of Ecuador which are part of the ECUARUNARI association were recently able to regain communal land titles or the return of estates—in some cases through militant activity.
== Contraindications == Apomorphine is contraindicated when used concomitantly with serotonin 5-HT3 receptor antagonists, including ondansetron, granisetron, and palonosetron, as this combination has been associated with profound hypotension and loss of consciousness. It is also contraindicated with allergies to the drug or its excipients, including sulfites. Intravenous administration of apomorphine is associated with blood clots and pulmonary embolism due to crystallization in the vein and is not recommended.
Unlike wealthy OECD countries, Australian law allows employers to designate employees as "casual", and take away universal rights such as paid holidays or job security in return for a nominal 25% extra pay even if they have lowered market pay in practice to nullify this "casual loading": in 2024, 22% of Australian employees were casual.
CNMamide (CNMa) is a cyclic neuropeptide identified by computational analysis of Drosophila melanogaster protein sequences and named after its C-terminal ending motif. A gene encoding CNMa was found in most arthropods and comparison among the precursor sequences of several representative species revealed high conservation, particularly in the region of the predicted mature peptide. Two conserved cysteine residues enveloping four amino acids form a disulfide bond and were shown to be important for binding of the peptide to its receptor. Expression of CNMa was confirmed in the larval and adult brain of D. melanogaster but the function of the peptide has not been elucidated yet.
Being South African, Player never played in the Ryder Cup in which American and European golfers compete against each other. Regarding the event, Player remarked, "The things I have seen in the Ryder Cup have disappointed me. You are hearing about hatred and war." He was no longer an eligible player when the Presidents Cup was established to give international players the opportunity to compete in a similar event, but he was non-playing captain of the International Team for the Presidents Cup in 2003, which was held on a course he designed, The Links at Fancourt, in George, South Africa. After 2003 ended in a tie, he was reappointed as captain for the 2005 Presidents Cup, and his team lost to the Americans 15.5 to 18.5. Both Player and Jack Nicklaus were appointed to captain their respective teams again in 2007 in Canada; the United States won.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.